While writing my weekly Biopharma Stock Watch article for our members, I stumbled across an exciting clinical-stage gene therapy company Krystal Biotech (Nasdaq: KRYS). Since we started following KRYS … [Read more...] about Krystal Biotech (NASDAQ: KRYS) is On Track to Bring the First “Off the Shelf” Gene Therapy to Market
Biopharma Stock Watch July 1st-4th
It suffices to say Q2 2019 (April-June) has been a wild ride. In 1Q19 the market bounced back with a vengeance from its low-point in December 2018 when it appeared the U.S and China were on the cusp … [Read more...] about Biopharma Stock Watch July 1st-4th
Biopharma Stock Watch June 17th-21st
MS Performance Tracker Showing Data From Friday June 14th After The Market Closed Two weeks into June the markets are continuing to recover from the painful volatility we experienced in April and … [Read more...] about Biopharma Stock Watch June 17th-21st
My #1 Mid-Cap Biotech Stock Pick For 2019
The four qualities that I assign the most weight when evaluating a biotech company for viability is 1) An efficacious product 2) Sufficient funding 3) Competent leadership and 4) Relationships with … [Read more...] about My #1 Mid-Cap Biotech Stock Pick For 2019
Could This Biotech Stock Get Bought For $5.5 Billion? Either Way I’m Buying It
On Friday May 24th, 2019 Novartis (NYSE: NVS) gained FDA approval of its gene therapy product " Zolgensma® " for spinal muscular atrophy (SMA), originally purchased from AveXis in 2018 for $8.7 … [Read more...] about Could This Biotech Stock Get Bought For $5.5 Billion? Either Way I’m Buying It
Biopharma Stock Watch May 27th-31st
A popular idea floating around the biotech community is that healthcare companies are insulated, or more so at least than other sectors, from a trade war with China. From a fundamental perspective, … [Read more...] about Biopharma Stock Watch May 27th-31st
DVAX Restructuring Surprise; Was A Sell-Off The Right Reaction?
Sometimes during the lifetime of a company significant shifts in priorities and resource allocation are made. I believe the ability to recognize the need for such changes and the wherewithal to carry … [Read more...] about DVAX Restructuring Surprise; Was A Sell-Off The Right Reaction?
Biopharma Stock Watch May 20th-24th
The past week of trading was a mixed bag. On Monday we saw what I would call a "flash crash". The DJI dropped over 600 points in the morning (-2.4%) and proceeded to have its worst day this year since … [Read more...] about Biopharma Stock Watch May 20th-24th
Biopharma Stock Watch May 6th-10th
Last Week Healthcare finally took a turn for the better. The XBI (S&P Biotech ETF) got off to a rough start declining 4 points but bounced back +3.86% by Friday's close. The IBB ( iShares … [Read more...] about Biopharma Stock Watch May 6th-10th
You must be logged in to post a comment.